Effect of sample size and P-value filtering techniques on the detection of transcriptional changes induced in rat neuroblastoma (NG108) cells by mefloquine.
BACKGROUND
There is no known biochemical basis for the adverse neurological events attributed to mefloquine. Identification of genes modulated by toxic agents using microarrays may provide sufficient information to generate hypotheses regarding their mode of action. However, this utility may be compromised if sample sizes are too low or the filtering methods used to identify differentially expressed genes are inappropriate.


METHODS
The transcriptional changes induced in rat neuroblastoma cells by a physiological dose of mefloquine (10 micro-molar) were investigated using Affymetrix arrays. A large sample size was used (total of 16 arrays). Genes were ranked by P-value (t-test). RT-PCR was used to confirm (or reject) the expression changes of several of the genes with the lowest P-values. Different P-value filtering methods were compared in terms of their ability to detect these differentially expressed genes. A retrospective power analysis was then performed to determine whether the use of lower sample sizes might also have detected those genes with altered transcription.


RESULTS
Based on RT-PCR, mefloquine upregulated cJun, IkappaB and GADD153. Reverse Holm-Bonferroni P-value filtering was superior to other methods in terms of maximizing detection of differentially expressed genes but not those with unaltered expression. Reduction of total microarray sample size (< 10) impaired the capacity to detect differentially expressed genes.


CONCLUSIONS
Adequate sample sizes and appropriate selection of P-value filtering methods are essential for the reliable detection of differentially expressed genes. The changes in gene expression induced by mefloquine suggest that the ER might be a neuronal target of the drug.
Dow
Geoffrey S
GS
Department of Parasitology, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. geoffrey.dow@na.amedd.army.mil
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D004622:Embryo, Mammalian; D020869:Gene Expression Profiling / Q000379:methods / Q000706:statistics & numerical data*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005910:Glioma / Q000235:genetics* / Q000378:metabolism; D006822:Hybrid Cells; D015767:Mefloquine / Q000494:pharmacology*; D051379:Mice; D009447:Neuroblastoma / Q000235:genetics* / Q000378:metabolism; D009474:Neurons / Q000166:cytology; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods / Q000706:statistics & numerical data; D051381:Rats; D012189:Retrospective Studies; D014158:Transcription, Genetic / Q000187:drug effects*
D000962:Antimalarials; D015767:Mefloquine